AC Immune’s (ACIU) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of AC Immune (NASDAQ:ACIU) in a research report sent to investors on Friday, Benzinga reports. HC Wainwright currently has a $16.00 price objective on the stock.

AC Immune Price Performance

AC Immune stock remained flat at $3.50 during midday trading on Friday. The company had a trading volume of 182,176 shares, compared to its average volume of 129,036. The company’s fifty day moving average is $3.61 and its two-hundred day moving average is $3.39. AC Immune has a 1-year low of $1.78 and a 1-year high of $5.14. The stock has a market capitalization of $295.58 million, a PE ratio of -4.93 and a beta of 1.03.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. bought a new position in AC Immune in the fourth quarter valued at approximately $48,000. Tower Research Capital LLC TRC grew its stake in AC Immune by 4,935.4% in the third quarter. Tower Research Capital LLC TRC now owns 19,638 shares of the company’s stock valued at $56,000 after purchasing an additional 19,248 shares in the last quarter. Virtu Financial LLC bought a new position in shares of AC Immune during the 4th quarter worth approximately $58,000. Nixon Peabody Trust Co. bought a new position in shares of AC Immune during the 4th quarter worth approximately $64,000. Finally, Balyasny Asset Management LLC bought a new position in shares of AC Immune during the 3rd quarter worth approximately $82,000. 19.17% of the stock is currently owned by institutional investors.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.